Welcome to our dedicated page for Apollo Commercial Real Estate Finance SEC filings (Ticker: ARI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apollo Commercial Real Estate Finance, Inc.'s SEC filings document results of operations, material events and governance for ARI, a Maryland corporation with common stock listed on the NYSE. Its 8-K reports furnish quarterly and annual financial results presentations, GAAP and non-GAAP earnings measures, exhibits and Inline XBRL cover data.
Other filings record material definitive agreements, including the amended and restated management agreement among the company, ACREFI Operating, LLC and ACREFI Management, LLC, as well as shareholder voting matters, capital-structure disclosures and governance matters tied to the completed sale of the commercial real estate loan portfolio.
Apollo Commercial Real Estate Finance, Inc. reported an equity award to its Chief Financial Officer, Treasurer and Secretary. On 12/30/2025, the executive acquired 34,825 shares of common stock at a price of $0, increasing his beneficial ownership to 81,666 shares. The reported beneficial ownership amount includes 69,709 restricted stock units granted under the company’s 2019 and 2024 Equity Incentive Plans. Each restricted stock unit represents the right to receive one share of common stock upon vesting, subject to the executive’s continued service and the terms of the applicable award agreements.
Apollo Commercial Real Estate Finance, Inc. insider activity: The company’s President & CEO, who is also a director, reported acquiring 109,452 shares of common stock on 12/30/2025 at a price of $0 per share. Following this transaction, the reporting person beneficially owns 339,161 common shares in total.
The reported holdings include 319,574 restricted stock units (RSUs) granted under Apollo Commercial Real Estate Finance, Inc.’s 2019 and 2024 Equity Incentive Plans. Each RSU gives the right to receive one share of common stock as it vests, as long as the executive continues to serve through the applicable vesting dates.
Apollo Commercial Real Estate Finance, Inc. disclosed that its President & CEO and director sold 52,072 shares of common stock on December 15, 2025. The transactions were reported with a sale code at a weighted average price of $10.1616 per share, with individual trade prices ranging from $10.08 to $10.21.
After these sales, the insider beneficially owns 229,709 shares of common stock. This total includes 210,122 restricted stock units granted under the company’s equity incentive plans, with each unit representing the contingent right to receive one share as it vests, subject to continued service. The sales were effected under a Rule 10b5-1 trading plan adopted on November 13, 2024.
A holder of ARI common stock has filed a notice under SEC Rule 144 to sell 52,072 common shares through Morgan Stanley Smith Barney LLC Executive Financial Services. The planned sale has an aggregate market value of $526,968.64 and is expected to take place on or around 12/15/2025 on the NYSE.
According to the notice, there are 138,943,831 common shares outstanding. The shares to be sold were acquired from the issuer on 01/27/2023 as restricted stock units, with the full 52,072 units recorded as acquired on that date and the consideration labeled as non-cash.
Apollo Commercial Real Estate Finance, Inc. (ARI) furnished materials announcing its financial results for the quarter ended September 30, 2025. The company provided a summary press release and a detailed investor presentation as Exhibits 99.1 and 99.2.
The information was furnished under Item 2.02 and is not deemed filed under the Exchange Act. It will not be incorporated by reference into Securities Act documents unless expressly stated.
Apollo Commercial Real Estate Finance, Inc. (ARI) reported a return to profitability for Q3 2025. Net income was $50.8 million (EPS $0.34) versus a net loss of $91.5 million a year ago, while nine‑month net income reached $97.5 million compared to a loss of $160.3 million in 2024. Net interest income fell to $40.0 million from $47.0 million, but results benefited from foreign currency and derivative line items and income from an equity method investment.
Total assets rose to $9.52 billion from $8.41 billion at year‑end, driven by growth in commercial mortgage loans, net ($8.15 billion) and real estate owned, held for investment ($827.7 million). Secured debt arrangements, net increased to $5.90 billion. Stockholders’ equity was $1.86 billion. The CECL allowances totaled $374.3 million (including $335.0 million specific and $39.3 million general).
The loan portfolio expanded to $8.30 billion carrying value, with 98% floating rate exposure, a 3.0 weighted‑average remaining fully‑extended term, and $1.03 billion of unfunded commitments. Property mix shifted with Residential at 30.5%, Office 24.5%, and Hotel 17.5%. A quarterly cash dividend of $0.25 per common share was declared. Shares outstanding were 138,943,831 as of October 29, 2025.
Apollo Commercial Real Estate Finance insider sale and holdings summary. Stuart Rothstein, President & CEO and a director, reported selling 52,073 shares of ARI common stock on 09/15/2025 at a weighted average price of $10.7785 under a Rule 10b5-1 plan adopted on 11/13/2024. Following the sale, the reporting person beneficially owns 281,781 shares, which includes 210,122 restricted stock units that convert to shares as they vest. The Form 4 was filed and executed by an attorney-in-fact on 09/16/2025.
Apollo Commercial Real Estate Finance, Inc. (ARI) Form 144 notice shows an intended sale of 52,073 common shares through Morgan Stanley Smith Barney with an aggregate market value of $564,471.32, representing sales to occur on or about 09/15/2025 on the NYSE. The shares were acquired as restricted stock units on 01/27/2023. The filing also discloses a prior 10b5-1 sale by Stuart A. Rothstein on 06/16/2025 of 52,074 shares for gross proceeds of $511,819.72. The filer certifies no undisclosed material adverse information and references a possible 10b5-1 plan.